Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 82159-09-9 Chemical Structure| 82159-09-9

Structure of Epalrestat
CAS No.: 82159-09-9

Chemical Structure| 82159-09-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM, and used for the treatment of diabetic neuropathy.

Synonyms: ONO2235

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Epalrestat

CAS No. :82159-09-9
Formula : C15H13NO3S2
M.W : 319.40
SMILES Code : C2=C(/C=C(/C=C1/C(N(CC(O)=O)C(S1)=S)=O)C)C=CC=C2
Synonyms :
ONO2235
MDL No. :MFCD00865484

Safety of Epalrestat

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300
Precautionary Statements:P501-P270-P264-P301+P310+P330-P405
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SUM159 cells 20 µM Epalrestat significantly suppressed the migration and invasion of SUM159 cells PMC5379972
MDA-MB231 cells 20 µM Epalrestat significantly suppressed the migration and invasion of MDA-MB231 cells PMC5379972
Rat Schwann cells 10-50 μM 4 hours To assess the effect of EPS on nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation, results showed that 10 and 50μM EPS significantly increased nuclear Nrf2 levels. PMC3863807
Rat Schwann cells 10-50 μM 24 hours To assess the effect of EPS on intracellular glutathione (GSH) levels, results showed that 10 and 50μM EPS significantly increased intracellular GSH levels. PMC3863807
Healthy control fibroblasts 10 μM 48 hours To evaluate the effect of Epalrestat on polyol metabolism and glycosylation. Results showed Epalrestat decreased intracellular polyol levels and increased GDP-mannose levels. PMC10313913
PMM2-CDG patient-derived fibroblasts 10 μM 48 hours To evaluate the effect of Epalrestat on polyol metabolism and glycosylation. Results showed Epalrestat decreased intracellular polyol levels and increased GDP-mannose levels. PMC10313913
Non-small cell lung cancer patient-derived tumor organoids (PDTO) 319.4 ng/mL (1 μmol/L) 6 days To evaluate the effect of Epalrestat in overcoming chemoresistance to carboplatin/paclitaxel in PDTOs. Results showed Epalrestat significantly enhanced chemosensitivity and inhibited PDTO growth and viability. PMC11369614
Bovine aortic endothelial cells (BAECs) 50 μM 8 hours To evaluate the time-dependent effect of EPS on GSH levels. Results showed a significant increase in GSH levels after 8 hours. PMC4309844
Bovine aortic endothelial cells (BAECs) 10, 50, 100 μM 24 hours To evaluate the effect of EPS on intracellular GSH levels. Results showed that 50 and 100 μM EPS significantly increased intracellular GSH levels by 2.7- and 8.4-fold, respectively. PMC4309844
PLC/PRF-5 cells 200 μM 24 hours Reduction in glycolytic flux and lactate secretion through AKR1B1 inhibition. PMC10820337
HepG2 cells 50 μM 24 hours Inhibition of AKR1B1 activity, reduction in lactate secretion and lipid deposition, reversal of the Warburg effect. PMC10820337
Human RA fibroblast-like synoviocytes (RAFLSs) 15–60 μmol/L 2-hour pretreatment followed by 4-hour LPS stimulation To evaluate the inhibitory effect of Epalrestat on LPS-induced inflammatory cytokine expression. Results showed Epalrestat concentration-dependently suppressed LPS-mediated p65 phosphorylation and downregulated gene expression of AR, TNF-α, IL-1β, and IL-6 without affecting cell viability. PMC10496504

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice DSS-induced colitis model Intraperitoneal injection 40 mg/kg Injected on Days 1, 3, 5, and 7 of DSS treatment Epalrestat significantly potentiated the protective effect of mannose against colitis, reducing weight loss, colon shortening, and histological damage, and decreasing the expression of GRP78, CHOP, and CASP12 in IECs and colonic TNF-α production. PMC9887054
SCID mice Breast cancer xenograft model Intragastric 50 mg/kg/d Once daily for 4 weeks Epalrestat significantly suppressed tumor growth and lung metastasis of MDA-MB231 cells PMC5379972
Zebrafish Pmm2 mutant zebrafish Direct addition to embryo media 10 μM or 40 μM 24 hours To evaluate the effect of Epalrestat on polyol metabolism and glycosylation. Results showed Epalrestat decreased polyol levels and increased GDP-mannose levels. PMC10313913
NSG mice A549 NSCLC xenograft model Oral or intraperitoneal injection 10 mg/kg body weight Twice administration, 40 days duration To evaluate the in vivo efficacy of Epalrestat in overcoming chemoresistance. Results showed both intraperitoneal and oral Epalrestat significantly inhibited tumor growth, with tumor inhibition directly proportional to intratumoral Epalrestat concentration. PMC11369614
BALB/c mice High-fructose diet and DEN-induced MASLD-HCC model Oral 50 mg/kg/day Once daily for 21 days Inhibition of AKR1B1 activity, reversal of high-fructose diet and DEN-induced MASLD-HCC, reduction in hepatic lipid deposition and metabolic markers. PMC10820337
Sprague Dawley rats Adjuvant-induced arthritis (AIA) model Oral 15.5 mg/kg/day Once daily for 27 days To assess the impact of Epalrestat monotherapy on arthritis severity in AIA rats. Results demonstrated Epalrestat significantly exacerbated joint swelling, bone destruction, and inflammatory markers (e.g., Th17 cell proportion and 4-HNE levels), but co-treatment with NAC reversed these effects and enhanced anti-arthritic efficacy. PMC10496504
Mice Brachial plexus root avulsion (BPRA) model Oral gavage 40 mg/kg bodyweight Once daily for 14 days Epalrestat is neuroprotective against BPRA injury by increasing autophagy level, alleviating neuroinflammation and rescuing MNs death in mice. PMC9648007

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03244358 Triple Negative Breast Cancer PHASE2 TERMINATED 2020-12-01 Sun Yat-sen University, Cancer... More >> Center, Guangzhou, Guangdong, 510060, China Less <<
NCT05777226 Charcot-Marie-Tooth Disease (C... More >>MT) Less << PHASE2 NOT_YET_RECRUITING 2025-04-26 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.13mL

0.63mL

0.31mL

15.65mL

3.13mL

1.57mL

31.31mL

6.26mL

3.13mL

References

 

Historical Records

Categories